# OnCo record fianlimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fianlimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fianlimab" ;
  schema:name "Fianlimab"@en ;
  schema:description "Fianlimab is Regeneron's LAG-3 blocking antibody, paired with the PD-1 blocker cemiplimab. A 60% phase 1 response rate in untreated melanoma prompted phase 3 trials, but the metastatic trial against pembrolizumab missed its progression endpoint in 2026."@en ;
  schema:url <https://onco.cc/drugs/fianlimab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-phase-3-trial-fianlimab-lag-3> ;
  onco:status "phase-3" ;
  onco:tag "failed-so-far" ;
  onco:modality "Monoclonal antibody (anti-LAG-3)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/lag3/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:trials <https://onco.cc/trials/fianlimab-phase3-melanoma/>, <https://onco.cc/trials/nct06246916/>, <https://onco.cc/trials/nct05800015/>, <https://onco.cc/trials/nct05608291/>, <https://onco.cc/trials/nct05785767/>, <https://onco.cc/trials/nct06161441/>, <https://onco.cc/trials/nct03916627/>, <https://onco.cc/trials/nct06190951/>, <https://onco.cc/trials/nct06769698/> .